{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:22:14Z","timestamp":1779175334581,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.bcmd.2021.102573","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T14:21:01Z","timestamp":1619533261000},"page":"102573","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Good treatment-free survival of monoclonal gammopathy of undetermined significance associated pure red cell aplasia after bortezomib plus dexamethasone"],"prefix":"10.1016","volume":"89","author":[{"given":"Lele","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nafei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhipeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liwei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2021.102573_bb0005","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1182\/blood-2016-05-717140","article-title":"Pure red cell aplasia","volume":"128","author":"Means","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.bcmd.2021.102573_bb0010","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/bjh.14012","article-title":"Monoclonal gammopathy-associated pure red cell aplasia","volume":"173","author":"Korde","year":"2016","journal-title":"Brit. J. Haematol."},{"key":"10.1016\/j.bcmd.2021.102573_bb0015","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1158\/1078-0432.CCR-12-2922","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease","volume":"19","author":"Agarwal","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcmd.2021.102573_bb0020","first-page":"37","article-title":"Acquired pure red cell apasia in patients with plasma cell neoplasm and long term remission with bortezomib therapy","volume":"3","author":"Sarthy","year":"2013","journal-title":"J. Hematol. Malignancies"},{"key":"10.1016\/j.bcmd.2021.102573_bb0025","doi-asserted-by":"crossref","first-page":"373","DOI":"10.7754\/Clin.Lab.2016.160730","article-title":"Pure red cell aplasia associated with monoclonal gammopathy of undetermined significance and literature review","volume":"63","author":"Gu","year":"2017","journal-title":"Clin. Lab."},{"key":"10.1016\/j.bcmd.2021.102573_bb0030","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1365-2141.2008.07216.x","article-title":"Acquired pure red cell aplasia: updated review of treatment","volume":"142","author":"Sawada","year":"2008","journal-title":"Brit. J. Haematol."},{"key":"10.1016\/j.bcmd.2021.102573_bb0035","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/bjh.13376","article-title":"Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004\/2006 by the Japan PRCA collaborative study group","volume":"169","author":"Hirokawa","year":"2015","journal-title":"Brit. J. Haematol."},{"key":"10.1016\/j.bcmd.2021.102573_bb0040","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3324\/haematol.2017.175810","article-title":"Rational management approach to pure red cell aplasia","volume":"103","author":"Balasubramanian","year":"2018","journal-title":"Haematologica."},{"key":"10.1016\/j.bcmd.2021.102573_bb0045","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3324\/haematol.11192","article-title":"Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group","volume":"92","author":"Sawada","year":"2007","journal-title":"Haematologica."},{"key":"10.1016\/j.bcmd.2021.102573_bb0050","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4137\/CMO.S7764","article-title":"Efficacy of bortezomib as first-line treatment for patients with multiple myeloma","volume":"7","author":"Painuly","year":"2013","journal-title":"Clin. Med. Insights Oncol."},{"key":"10.1016\/j.bcmd.2021.102573_bb0055","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00277-020-04105-3","article-title":"Immunosuppression therapy is effective for both acquired tumor-associated and primary pure red cell aplasia: a match pair case-control study","volume":"99","author":"Chen","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bcmd.2021.102573_bb0060","first-page":"1498","article-title":"Treatment of pure red cell aplasia associated with multiple myeloma with biclonal gammopathy using cyclosporine A: a case report","volume":"8","author":"Lv","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.bcmd.2021.102573_bb0065","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00277-013-1721-5","article-title":"Pure red cell aplasia associated with CD20+ myeloma: complete remission with rituximab","volume":"92","author":"So","year":"2013","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bcmd.2021.102573_bb0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.14740\/jh356w","article-title":"Clinical resolution of red cell aplasia associated del 17p multiple myeloma, when treated with bortezomib and dexamethasone","volume":"7","author":"Ladha","year":"2018","journal-title":"J. Hematol."},{"key":"10.1016\/j.bcmd.2021.102573_bb0075","first-page":"353","article-title":"Pure red blood cell aplasia associated with paraproteinemia: in vitro studies of erythropoiesis","volume":"17","author":"Balducci","year":"1984","journal-title":"Haematologia."},{"key":"10.1016\/j.bcmd.2021.102573_bb0080","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1046\/j.1537-2995.1991.31491213304.x","article-title":"A cryoglobulin with cold agglutinin and erythroid stem cell suppressant properties","volume":"31","author":"Umlas","year":"1991","journal-title":"Transfusion."},{"key":"10.1016\/j.bcmd.2021.102573_bb0085","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/bmt.2011.176","article-title":"Successful treatment of isohemagglutinin-mediated pure red cell aplasia after ABO-mismatched allogeneic hematopoietic cell transplant using bortezomib","volume":"47","author":"Poon","year":"2012","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bcmd.2021.102573_bb0090","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/tme.12121","article-title":"Subcutaneous bortezomib is highly effective for pure red cell aplasia after ABO-incompatible haematopoietic stem cell transplantation","volume":"24","author":"Khan","year":"2014","journal-title":"Transfus. Med."},{"key":"10.1016\/j.bcmd.2021.102573_bb0095","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/tme.12216","article-title":"Successful treatment of refractory pure red cell aplasia with bortezomib after allogeneic haematopoietic cell transplantation in a patient with alpha-beta subcutaneous panniculitis-like T cell lymphoma","volume":"25","author":"Shahan","year":"2015","journal-title":"Transfus. Med."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979621000395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979621000395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:36:35Z","timestamp":1761050195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979621000395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":19,"alternative-id":["S1079979621000395"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2021.102573","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Good treatment-free survival of monoclonal gammopathy of undetermined significance associated pure red cell aplasia after bortezomib plus dexamethasone","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2021.102573","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102573"}}